Introduction {#Sec1}
============

The worldwide incidence of kidney stone disease (KSD) is rising \[[@CR1]\]. The use of ureteroscopy (URS) for KSD has also risen, whilst shockwave lithotripsy (SWL) use has fallen \[[@CR2]\]. This trend has resulted from improvement of technique, minimization of scopes and better laser fragmentation technology \[[@CR3]\]. While stones in the ureter and most stones up to 2 cm in the kidney are suitable for both URS and SWL, several prospective randomized controlled trials have demonstrated the superiority of URS over SWL in terms of stone free rate (SFR) and retreatment rates \[[@CR4]\].

Majority of stones might be amenable for either URS or SWL and although treatment is tailored after patient counseling, for patients suitable for both modalities, a major factor in treatment selection is the cost associated with it, especially with healthcare resources already stretched to its limit. These costs can vary greatly depending on the initial purchase price, cost of consumables and repair, durability of the instruments, the negotiated discounts available from manufacturers and the reimbursement received by the providers.

While cost is increasingly an important factor in the decision-making, to date, there has been no review comparing the cost of URS and SWL. Although individual cost of URS and SWL has been mentioned, there is no clear way to compare costs due to discrepancies across various healthcare systems and partly because indirect costs are difficult to measure \[[@CR5]--[@CR8]\]. In the absence of clear cost comparison, we wanted to look the cost of surgical stone management as has been reported by the authors in studies comparing both URS and SWL. To this end, we perform a systematic review and meta-analysis of all studies reporting on comparative cost of treatment between URS and SWL.

Methods and Materials {#Sec2}
=====================

Evidence acquisition: criteria for considering studies for this review {#Sec3}
----------------------------------------------------------------------

PopulationAdults with ureteral or renal urolithiasisInterventionUreteroscopyComparatorShockwave lithotripsyOutcomeCostStudy designSystematic review and meta-analysis

Inclusion criteria:all published articles written in the English languagestudies reporting on comparative cost of treatment between URS and SWLURS will include rigid, semi-rigid and flexible.

Exclusion criteria:studies examining treatment for non-urolithiasis conditionsolder studies using the same data as a more recent study---the longest cohort was chosen to avoid duplicationgrey literature and decision analysis models which did not have real patient data

Search strategy and study selection {#Sec4}
-----------------------------------

The systematic review was performed according to the Cochrane review guidelines \[[@CR9]\]. The search strategy was conducted to find relevant studies from Ovid medline without revisions (2001--2017), PubMed (2001--2017), EMBASE (2001--2017), Cochrane Library (2017), CINAHL (2001--2017), Clinicaltrials.gov, Google Scholar and individual urologic journals.

The search terms used included: 'ureteroscopy, 'URS, 'ureterorenoscopy, 'retrograde intrarenal surgery', 'RIRS', 'shockwave lithotripsy', 'SWL', 'ESWL', 'cost', 'calculi\*', 'stone\*', 'nephrolithiasis' and 'urolithiasis'. Boolean operators (AND, OR) were used to refine the search.

As the cost data prior to 2001 was not relevant anymore, the search was limited to English language articles published between January 2001 and December 2017. Authors of the included studies were contacted in the case of data not being available or clear. If the authors did not reply data was estimated from the graphs and other data provided in the study and if the data could not be estimated, then the study was excluded from analysis. Our study was registered with PROSPERO (International prospective register of systematic reviews)---registration number---CRD 42017080350.

Two experienced reviewers (RG and BS) identified all studies. All studies that appeared to fit the inclusion criteria were included for full review. Each reviewer independently selected studies for inclusion in the review and all discrepancies were resolved with mutual agreement and consensus with the third author (PJ) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA flowchart of the included studies

Data extraction and analysis {#Sec5}
----------------------------

The following variables were extracted from each study: year of publication, country of study, study period, treatment modality, price/cost, age, stone size, location of stone, stone free rate, complications, hospital stay, retreatment rate and operative time. Bias analysis was performed using the GRADE guidelines \[[@CR10]\].

Cost was converted to US dollars based on the mean exchange rate of the year of publication. Cost was rounded to the nearest dollar. Data was collated using Microsoft Excel (version 12.2.4) and analysed using Revman (version 5.0) and SPSS (version 21). Those studies with no standard deviations for cost were not given weight in the forest plot analysis. Forest plots were generated in Revman 5.3.

Continuous data was presented as standard mean difference and for dichotomous data risk difference was used. Data heterogeneity was assessed using a Chi squared test. If there were no significant heterogeneity then random effects were used. If there was a significant result, this was adjusted for using standard mean difference and random effects on forest plot analysis.

Results {#Sec6}
=======

Study characteristics {#Sec7}
---------------------

There were 12 studies examining the cost of URS vs. SWL \[[@CR11]--[@CR22]\]. These took place in the USA \[[@CR11], [@CR12], [@CR20], [@CR21]\], China, \[[@CR13]--[@CR15], [@CR19]\], Egypt \[[@CR16]\], Taiwan \[[@CR17]\] and the UK \[[@CR18], [@CR22]\]. Seven of the included studies were retrospective cohort studies \[[@CR12]--[@CR14], [@CR18]--[@CR21]\] two were prospective cohort studies \[[@CR17], [@CR22]\] and the remaining three \[[@CR11], [@CR15], [@CR16]\]. The studies took place over a mean 2-year period. Overall there were 2012 patients, with 1243 undergoing SWL and 769 undergoing URS. Studies were subdivided further according to stone size (see Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).Table 1URS vs. SWL study demographicsStudyCountryStudy typeStudy periodPatients, *n*SWL, *n*URS, *n*Type of URSPearle et al. 2001 \[[@CR11]\]USAProspective randomized trial1995--2000643232Semi-rigidParker et al. 2004 \[[@CR12]\]  \< 10 mmUSARetrospective cohort1997--20011547381Flexi/semirigid -unclearParker et al. 2004 \[[@CR12]\] ≥10 mmUSARetrospective cohort1997--2001663828Flexi/semirigid -unclearWu et al. 2004 \[[@CR13]\]ChinaRetrospective cohort2002--2003804139Semi-rigidWu et al. 2005 \[[@CR14]\]  \< 10 mmChinaRetrospective cohort2002--20031136845Semi-rigidWu et al. 2005 \[[@CR14]\] ≥10 mmChinaRetrospective cohort2002--20031075156Semi-rigidLee et al. 2006 \[[@CR15]\]ChinaProspective randomized trial2001--2003422220Semi-rigidSalem 2009 \[[@CR16]\] \<10 mmEgyptProspective randomized trialN/A1105852Semi-rigidSalem 2009 \[[@CR16]\] ≥10 mmEgyptProspective randomized trialN/A904248Semi-rigidHuang et al. 2009 \[[@CR17]\]  \< 10 mmTaiwanProspective cohort1998--199924120140Semi-rigidHuang et al. 2009 \[[@CR17]\] ≥10 mmTaiwanProspective cohort1998--199920715948Semi-rigidKoo et al. 2011 \[[@CR18]\]UKRetrospective cohortN/A885137FlexibleCui et al. 2014 \[[@CR19]\]ChinaRetrospective cohort2010--20121608080RigidCone et al. 2014 \[[@CR20]\]USARetrospective cohort2010--20111587880FlexibleCone et al. 2017 \[[@CR21]\]USARetrospective cohort2010--20111135162Flexible (*n* = 39), semirigid (*n* = 23)Chan et al. 2017 \[[@CR22]\]UKProspective cohort2008--201321919821FlexibleTotal20121243769*N/A* not available Table 2SWL vs. URS patient and stone demographicsStudyAge, year ± SD (range)Stone size, mm ± SD (range)SWLURSSWLURSLocationPearle et al. 2001 \[[@CR11]\]41.2 ± 14.941.2 ± 12.87.4 ± 2.36.4 ± 2.7Distal ureterParker et al. 2004 \[[@CR12]\]  \< 10 mm50 ± 1744 ± 15\< 10\< 10Proximal ureterParker et al. 2004 \[[@CR12]\] ≥10 mm55 ± 1548 ± 16\> 10\> 10Proximal ureterWu et al. 2004 \[[@CR13]\]515112.8 ± 0.415.1 ± 0.5Proximal ureterWu et al. 2005 \[[@CR14]\]  \< 10 mm47.5 ± 1.551.0 ± 2.06.9 ± 0.27.2 ± 0.2Proximal UreterWu et al. 2005 \[[@CR14]\]  ≥ 10 mm51.5 ± 1.953.8 ± 1.512.1 ± 0.317.0 ± 0.7Proximal UreterLee et al. 2006 \[[@CR15]\]54.2 ± 16.748.5 ± 13.317.9 ± 3.918.5 ± 2.9Proximal ureterSalem, 2009 \[[@CR16]\] \< 10 mm42.8 (37--60)41.2 (36--60)6.2 (5--9)6.8 (6--9)Proximal ureterSalem 2009 \[[@CR16]\]  ≥ 10 mm45.4 (37--55)36.7 (20--48)12.5 (11--20)12.2 (12--20)Proximal ureterHuang et al. 2009 \[[@CR17]\]  \< 10 mm52.5 ± 16.149.5 ± 12.7\<10\<10Proximal UreterHuang et al. 2009 \[[@CR17]\] ≥ 10 mm52.5 ± 16.149.5 ± 12.7\> 10\> 10Proximal ureterKoo et al. 2011 \[[@CR18]\]51.2 ± 14.956.6 ± 15.9\< 20\< 20Ureteric (all locations)Cui et al. 2014 \[[@CR19]\]40.6 ± 9.841.5 ± 10.59.8 ± 3.510.2 ± 4.3Proximal ureterCone et al. 2014 \[[@CR20]\]54 ± 1547 ± 117.0 ± 0.277.27 ± 0.27RenalCone et al. 2017 \[[@CR21]\]53 ± 1354 ± 167.64 ± 3.327.50 ± 2.22Proximal ureterChan et al. 2017 \[[@CR22]\]54.1 ± 13.362.2 ± 1512.4 ± 2.413.1 ± 3.7Lower pole renalTotal49.448.510.211.0

Patient and stone demographics {#Sec8}
------------------------------

The mean age of patients in the SWL group was 49.4 years (range: 37--60), and the URS group was 48.5 years (range: 20--60). Stone size was similar between the two groups with a mean size of 10.2 mm (range: 6.2--20 mm) for SWL and 11 mm for URS (range: 6.4--20 mm) (Table [2](#Tab2){ref-type="table"}). There were five studies examining stones smaller than 10 mm \[[@CR11], [@CR12], [@CR14], [@CR16], [@CR20]\], two studies examining stones less than 15 mm \[[@CR20], [@CR21]\] and five studies examining stones 10 mm and larger \[[@CR12], [@CR14], [@CR16], [@CR17], [@CR22]\].

Eight studies compared treatment of proximal ureteric stones only \[[@CR12]--[@CR17], [@CR19], [@CR21]\]. The others compared distal stones \[[@CR11]\], ureteric stones of all locations \[[@CR18]\] and renal stones \[[@CR20], [@CR22]\].

Intra- and post-operative characteristics {#Sec9}
-----------------------------------------

The studies predominantly used semi-rigid URS. Six studies used semi-rigid URS, three used flexible URS, one study using rigid URS, one study used either flexible or semi-rigid URS and one study did not specify the type of URS (Table [1](#Tab1){ref-type="table"}).

The mean initial SFR was significantly higher for URS (84%) vs. SWL (60%). Comparison between the randomized trials demonstrated significantly higher stone free rates for URS (*I*^2^ = 30%: risk difference = 0.17, 95% CI 0.08--0.26, *p* \< 0.001) (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}a).Table 3SWL vs. URS intra- and post-operative characteristicsStudyInitial SFR (%)Complications, *n* (%)Retreatment (%)SWLURSSWLURSSWLURSPearle et al. 2001 \[[@CR11]\]66%69%3 (9%)8 (25%)NoneNoneParker et al. 2004 \[[@CR12]\]  \< 10 mm60%90%20 (27.4%)19 (23.5%)N/AN/AParker et al. 2004 \[[@CR12]\] ≥10 mm45%93%17 (44.7%)12 (42.9%)N/AN/AWu et al. 2004 \[[@CR13]\]61%92%NoneNone39%8%Wu et al. 2005 \[[@CR14]\]  \< 10 mm85.30%91.10%N/AN/A14.7%8.9%Wu et al. 2005 \[[@CR14]\] ≥10 mm35.20%76.80%N/AN/A64.8%23.2%Lee et al. 2006 \[[@CR15]\]31.80%35%2 (9%)13 (65%)31.80%40%Salem, 2009 \[[@CR16]\] \< 10 mm80%100%N/AN/A40.48%8.33%Salem 2009 \[[@CR16]\] ≥ 10 mm60%88%54 (93%)27 (52%)20.69%NoneHuang et al. 2009 \[[@CR17]\]  \< 10 mm75.60%95.00%N/AN/A24.4%5%Huang et al. 2009 \[[@CR17]\] ≥ 10 mm66.70%85.40%N/AN/A33.3%14.6%Koo et al. 2011 \[[@CR18]\]45.10%64.90%4 (8%)4 (11%)7.50%2.50%Cui et al. 2014 \[[@CR19]\]77.50%97.50%30 (38%)31 (39%)21.60%16.20%Cone et al. 2014 \[[@CR20]\]55%95%N/AN/A12.80%5%Cone et al. 2017 \[[@CR21]\]47.10%88.70%N/AN/AN/AN/AChan et al. 2017 \[[@CR22]\]62.60%76.20%6 (3%)3 (14%)40%10%Total60% ± 15%84% ± 16%136 (23%)117 (30%)27% ± 16%11% ± 11%*p* (χ^2^)\< 0.0010.26\<0.001OR (95% CI)4.58 (3.52--5.97)0.72 (0.50--1.03)3.43 (2.48--4.74)*p* (forest plot)\< 0.0010.07\< 0.001*N/A* not available, *SWL* Shockwave lithotripsy, *URS* Ureteroscopy Fig. 2**a**--**c** forest plot of SFR, complications and re-treatment

The total number of complications for each group were 136 for SWL and 117 for URS. The mean complication rates were 23% for SWL and 30% for URS. There was no statistical difference between the two when examining the randomized trials (*I*^2^ = 96%, risk difference = 0.14, 95% CI − 0.03--0.31, *p* = 0.11) (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}b).

There were higher retreatment rates for SWL (27%) than for URS (11%). Meta-analysis of the randomized trials demonstrated no significant difference between URS and SWL (*I*^2^ = 91%, risk difference = 0.12, 95% CI − 0.10--0.33, *p* = 0.29) (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}c).

Cost and hospital stay {#Sec10}
----------------------

URS (mean: \$2801) was significantly cheaper than SWL (mean: \$3637) (standard mean difference = 1.64, 95% CI 0.13--3.15, *I*^2^ = 99%, *p* = 0.03) (Table [4](#Tab4){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Cost breakdown is itemized in Table [5](#Tab5){ref-type="table"}.Table 4SWL vs. URS cost data and hospital stayStudyPrice (\$)P (SWL vs. URS cost) from original studiesHospital stay, days ± SD (range) SWL ± SDURS ± SDSWLURS**Pearle et al. 2001** \[[@CR11]\]\$7343\$6088N/A94% day-case75% day-caseParker et al. 2004 \[[@CR12]\]  \< 10 mm\$14,900 ± 7600\$9200 ± 4400\<0.001N/AN/AParker et al. 2004 \[[@CR12]\] ≥ 10 mm\$16,900 ± 7000\$10,000 ± 7100\<0.0001N/AN/AWu et al. 2004 \[[@CR13]\]\$1401 ± 104\$953 ± 350.001N/AN/AWu et al. 2005 \[[@CR14]\]  \< 10 mm\$1091.00 ± 39\$955 ± 400.01N/AN/AWu et al. 2005 \[[@CR14]\] ≥10 mm\$1771 ± 95\$1153 ± 62\<0.001N/AN/ALee et al. 2006 \[[@CR15]\]\$1637\$2154N/A1.8 ± 0.44.7 ± 2Salem 2009 \[[@CR16]\]\$1300\$1140\<0.05N/AN/AHuang et al. 2009 \[[@CR17]\]  \< 10 mm (overall)\$642 ± 288\$630 ± 1590.472.0 ± 0.72.9 ± 1.4Huang et al. 2009 \[[@CR17]\] ≥ 10 mm (overall)\$734 ± 303\$698 ± 1670.322.0 ± 0.72.9 ± 1.4Huang et al. 2009 \[[@CR17]\]  \< 10 mm (upper ureter)\$632 ± 114\$688 ± 2120.042.0 ± 0.72.9 ± 1.4Huang et al. 2009 \[[@CR17]\] ≥ 10 mm (upper ureter)\$690 ± 130\$846 ± 2320.032.0 ± 0.72.9 ± 1.4Koo et al. 2011 \[[@CR18]\]\$4059 ± 2106\$665 ± 624\<0.001N/AN/ACui et al. 2014 \[[@CR19]\]\$120 ± 25\$1180 ± 258\<0.050.25 ± 0.72.8 ± 2.3Cone et al. 2014 \[[@CR20]\]\$3167\$4470N/AN/AN/ACone et al. 2017 \[[@CR21]\]\$3167\$4470N/AN/AN/AChan et al. \[[@CR22]\]\$931\$1564\<0.0010 ± 0.42.4 ± 3.5Total\$3637\$2801.331.23.1*N/A* not available Fig. 3Forest plot of cost between SWL and URS Table 5SWL vs. URS Itemized cost breakdown (as reported by individual studies)StudyCost breakdown and calculation for each study (based on the individual studies)Study populationSWLURSPearle et al. 2001 \[[@CR11]\]Hospital fee, anaesthesia professional fee, urology professional feeHospital fee, anaesthesia professional fee, urology professional fee, office stent removal, urology fee for stent removalAdults with solitary radiopaque distal ureteric calculus below bony pelvis ≤ 15 mmParker et al. 2004 \[[@CR12]\]Initial procedure, additional procedures, radiographs, clinicsInitial procedure, additional procedures, radiographs, clinicsAdults with solitary radiopaque stone between ureteropelvic junction and sacroiliac jointWu et al. 2004 \[[@CR13]\]Pre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatmentPre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatmentAdults with solitary upper ureteral (UPJ to SIJ) stone \> 1 cm. Patient choice on treatment optionWu et al. 2005 \[[@CR14]\]Pre-op evaluation, operation, perioperative monitoring, postoperative care, office visits and any ancillary/retreatment proceduresPre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatmentAdults with single, primary, upper ureteral radiopaque calculus. Patient choice on treatment optionLee et al. 2006 \[[@CR15]\]Hospital charges, operating room, radiology, surgeon, anaesthesia and auxiliary proceduresHospital charges, operating room, radiology, surgeon, anaesthesia, auxiliary procedures and SWL machineAdults with a solitary upper ureteral stone (above the border of L5 vertebra), ≥ 15 mmSalem, 2009 \[[@CR16]\]Pre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatmentPre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatment Adults with single radiopaque upper ureteral stone 5--20 mmHuang et al. 2009 \[[@CR17]\]Pre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatment Pre-op evaluation, operation, perioperative monitoring, postoperative care, office visits, ancillary procedures and retreatmentAdults with ureteral stones (upper ureter defined as above). Unclear if solitary or lucency on XRKoo et al. 2011 \[[@CR18]\]Procedural + overheads Procedural + overheadsAdults with symptomatic radiopaque renal calculi \< 20 mmCui et al. 2014 \[[@CR19]\]N/AN/AAdults with single radiopaque stone 8--15 mm. Patient choice on treatmentCone et al. 2014 \[[@CR20]\]Surgeons fee, anaesthesia, facility cost, stent placementSurgeons fee, anaesthesia, facility cost, stent placementAdults with radiopaque renal stones \< 15 mm. Patient choice on treatmentCone et al. 2017 \[[@CR21]\] N/A N/AAdults with radiopaque ureteral stones \< 15 mm. Patient choice on treatmentChan et al. 2017 \[[@CR22]\]Cost per procedure (NHS tariff)Cost per procedure (NHS tariff)Adults with single radiopaque or radiolucent lower pole renal stones 10--20 mm

The mean hospital stay was significantly shorter for SWL (1.2 days, range: 0--2) compared to URS (3.1 days, range: 0--4.7).

Sub-analyses {#Sec11}
------------

### Stone size {#Sec12}

Subanalysis of studies comparing SWL and URS was possible for stone size smaller than 10 or 10 mm and larger. Both groups favoured URS in terms of cost (\< 10 mm: Std mean diff = 0.90, 95% CI 0.68--1.12, *I*^2^ = 98%, *p* \< 0.001; ≥ 10 mm: Std mean diff = 0.78, 95% CI 0.51--1.04, *I*^2^ = 99%, *p* \< 0.001).

### Proximal ureteric stones {#Sec13}

Proximal ureteric stones treated with URS had significantly cheaper costs (Std. mean diff = 0.99, 95% CI 0.82--1.15, *p* \< 0.001).

### Risk of bias analysis {#Sec14}

Risk of bias was analysed in each study (Fig. [4](#Fig4){ref-type="fig"}). The overall the risk of bias was high. There were only three prospective randomized trials with the remaining studies being prospective cohort studies (*n* = 2) and retrospective studies (*n* = 7). The randomized trials scored a 'low' certainty on bias analysis using GRADE, and the observational studies scored a 'very low' certainty.Fig. 4Risk of bias analysis

None of the studies were blinded, although given that these were surgical studies blinding is not always feasible. The data was complete for all studies except these four studies \[[@CR13], [@CR15], [@CR19], [@CR20]\], however none of the studies provided a patient/study participant flow diagram to allow for easy assessment of attrition bias.

Reporting bias was suspected in two studies \[[@CR19], [@CR22]\]. Cui et al. \[[@CR19]\]. performed a retrospective study with 80 patients in each treatment arm and it is possible that other patients were treated during the same time period but excluded from the study. Thus there is a high risk of selection and reporting bias. Chan et al. \[[@CR22]\]. had very large numbers of SWL but relatively few patients undergoing URS, which reduced the power of the study increased the risk of Type II statistical error.

Discussion {#Sec15}
==========

Principal findings {#Sec16}
------------------

This study is the first meta-analysis comparing cost of URS and SWL as reported by the authors and has comprehensively examined all objective outcome measures. The analysis shows that URS has higher SFR and lower retreatment rates in comparison to SWL. While the cost was significantly lower for URS, the complication rates were relatively higher than SWL although this was not statistically significant. URS seem to be more cost effective for treatment of stones of all sizes.

Meaning of the study: implications for clinicians and policymakers {#Sec17}
------------------------------------------------------------------

This review has demonstrated the overall advantage of URS in terms of cost, SFR and retreatment rates. While the calculation of costs across studies is not standardized, the comparison within each study is done using similar parameters. These costs might vary across various healthcare systems but considering that the studies have been reported from different countries, the results are generalizable to most patients. Treatment decisions should be individualized for patients after informed consent and should be based on clinical needs rather than economical compulsions.

Strengths and limitations {#Sec18}
-------------------------

The strength of our review is the systematic approach used to review the literature on the cost comparison for URS and SWL. Two independent researchers not involved in any of these reported studies performed the data extraction. Furthermore, a meta-analysis and risk of bias has also been conducted with sub-analysis of available stone parameters.

An obvious weakness of our review is the dependence on primary studies, which did not have standardized reporting of cost and comes from different healthcare setups where the treatment costs are variable. Similarly, the cost of URS has changed dramatically in the study period and new technologies adopted in the past few years have had a big influence on the cost.

The non-randomized studies were potentially prone to bias in patient selection and outcome reporting and the randomized studies were not blinded. Only Parker et al. \[[@CR12]\] had a chance of blinding as their subjects underwent general anaesthesia (GA) for both URS and SWL, whereas all other studies used sedation for SWL rather than GA. While cost was calculated, their quality of life was not reported, which can be especially affected in patients undergoing URS with a post-operative stent insertion. None of the studies provided sample size/power calculations or CONSORT \[[@CR23]\] flow diagrams for patient involvement in the study.

There was significant heterogeneity between the studies for all outcome measures. For continuous data like the cost and hospital stay, this was adjusted for by using standard mean difference and fixed effects analysis on forest plot. Heterogeneity would be expected given differences in available equipment, which could thereby affect outcomes and cost variation between countries. Cost also varied depending on what studies included in their 'cost', which would range from the procedure itself to the entire initial hospital stay plus office visits/additional hospital stays. Despite a lack of randomization, which is often unachievable in invasive surgical studies, \[[@CR24]\] the outcome measures were objective and often dichotomous (i.e., SFR, retreatment rate, complication rate), therefore reducing the risk of a placebo effect.

Strengths and weaknesses in relation to other studies, discussing important differences in results {#Sec19}
--------------------------------------------------------------------------------------------------

Hospital stay was significantly longer for URS but given that only three studies provided this data and there was a high heterogeneity between the studies (*χ*^2^: *p* \< 0.001, *I*^2^ = 80%), this result must be open to interpretation. Modern studies have demonstrated that day-case URS is becoming increasingly more feasible and therefore more comparable to SWL \[[@CR25]\].

Decision analysis models were excluded as they do not include patient data. However, published decision analysis models can provide a useful tool to compare SWL and URS. Lotan et al. \[[@CR26]\] demonstrated that above a SFR of 80% URS is more cost-effective than SWL. Another model by Cone et al. \[[@CR20]\] demonstrated that a 67% SFR using SWL would be cost effective and a SFR \< 71% using URS would not be cost effective, concluding that URS could be considered as a first-line treatment for renal or ureteric calculi \< 1.5 cm in patients who desire to be stone free. Mean SFR for studies in this meta-analysis was 84%. Seven studies crossed this cost-effectiveness threshold, covering proximal ureteric stones and all renal stones \[[@CR12], [@CR13], [@CR16], [@CR17], [@CR19]--[@CR21]\]. The results also demonstrate a trend, reflected in another systematic review, that higher case volume results in higher SFR and fewer complications \[[@CR27]\].

Although SWL is less invasive, over the last decade there is a shift from physician delivered to technician delivered treatment, perhaps coupled with a relative lack in technological advancements and investment in SWL when compared to URS. Optimization of SWL with training and proper maintenance can offer better treatment outcomes, which in turn can decrease the overall cost of SWL \[[@CR28]\].

The limitations of our study relate to the heterogeneous nature of the studies included from different countries with variable practice patterns. The SFR was not defined consistently across studies \[[@CR29]\]. Similarly the measurement of cost varied across studies although for each study as the cost of procedures would vary between healthcare systems and the author's account of cost was taken into consideration.

Future studies {#Sec20}
--------------

There are large numbers of retrospective case series within the surgical literature suggesting ways to minimize costs \[[@CR29], [@CR30]\]. This constitutes a very poor evidence base on which to base recommendations. There needs to be a trend towards larger randomized trials that are powered towards the desired outcome, and therefore able to accurately assess the true cost-effectiveness. In addition to comparing the cost of SWL and URS it needs to include quality of life measurements, which is a significant cause of morbidity in especially in URS.

Conclusion {#Sec21}
==========

There is limited evidence to suggest that URS is less expensive than SWL. However, due to lack of standardization, studies seem to be contradictory and further randomized studies are needed to address this issue.
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